scholarly journals Family history of venous thromboembolism and mortality after venous thromboembolism: a Swedish population-based cohort study

2016 ◽  
Vol 43 (4) ◽  
pp. 469-475 ◽  
Author(s):  
Bengt Zöller ◽  
Mirnabi Pirouzifard ◽  
Jan Sundquist ◽  
Kristina Sundquist
Keyword(s):  
Cohort Study ◽  
Venous Thromboembolism ◽  
Family History ◽  
Population Based ◽  
Swedish Population ◽  
History Of

Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study

2006 ◽  
Vol 105 (1) ◽  
pp. 69-80 ◽  
Author(s):  
Jane C. Figueiredo ◽  
Marguerite Ennis ◽  
Julia A. Knight ◽  
John R. McLaughlin ◽  
Nicky Hood ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Cohort Study ◽  
Family History ◽  
Population Based ◽  
Young Age ◽  
Age At Diagnosis ◽  
Cancer Outcomes ◽  
Breast Cancer Outcomes ◽  
History Of

Family History of Venous Thromboembolism (VTE) and the Risk of VTE Recurrence in Patients with a First Unprovoked VTE: A Multicenter Prospective Cohort Study

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 2299-2299
Author(s):  
Karine Gauthier ◽  
Elham Sabri ◽  
Susan R. Kahn ◽  
Philip S Wells ◽  
David Anderson ◽  
...  
Keyword(s):  
Cohort Study ◽  
Venous Thromboembolism ◽  
Family History ◽  
Conflicts Of Interest ◽  
Anticoagulation Therapy ◽  
Degree Relative ◽  
National Cohort ◽  
History Of ◽  
Recurrent Vte ◽  
Second Degree

Abstract Abstract 2299 Introduction: The duration of anticoagulation after unprovoked venous thromboembolism (VTE) has been characterized as the most important unanswered question in clinical thrombosis management. This has led to research to identify predictors of recurrent VTE to identify high-risk patients who might warrant indefinite anticoagulation. Many clinicians assume that a family history of VTE is a predictor of recurrent VTE. This study aims to assess the value of family history as a predictor for recurrent VTE. Methods: Prospective multi-center multi-national cohort study recruited patients with a first objectively proven unprovoked VTE who completed 5 to 7 months of anticoagulation therapy. A detailed family history of VTE was completed for every subject. The information recorded included the number of affected relatives, whether they were first or second degree relatives and if the VTE was unprovoked or secondary. Patients were then followed for recurrent VTE. Results: 664 subjects were enrolled between October 2001 and March 2006, 649 subjects were followed for a mean duration of 3.8 years (3.6–3.98 95% C.I.). The mean age of subjects in this cohort was 53 years (min-max 18–95) and 49% of subjects were females. A family history of VTE in at least 1 first-degree relative was recorded for 112 (17.3%) subjects. A total of 142 (21.9%) suspected VTE events were adjudicated as recurrences. The recurrence rate was 5.94% (4.89–7.15 95% C.I.) per patient-year for patients without any family history of VTE, and it was 4.82% (3.02–7.30 95% C.I.) per patient-year in patients with a family history of VTE in at least 1 first-degree relative. In secondary analyses, neither a family history of unprovoked VTE, multiple unprovoked VTE, in first-degree nor second-degree relatives was a predictor of recurrent VTE. A multivariate analysis was performed to adjust for known risk factors for VTE recurrence, but the adjusted hazard ratios were again not significantly different. Conclusion: A family history of VTE is not a predictor for recurrent VTE, and therefore should not be used to segregate unprovoked VTE patients in high- and low-risk categories. Disclosures: No relevant conflicts of interest to declare.

Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study

The Lancet ◽  
2002 ◽  
Vol 360 (9337) ◽  
pp. 891-894 ◽  
Author(s):  
Kjell Bergfeldt ◽  
Bosse Rydh ◽  
Fredrik Granath ◽  
Henrik Grönberg ◽  
Lukman Thalib ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Cohort Study ◽  
Family History ◽  
Cancer Patients ◽  
Population Based ◽  
Breast Cancer Patients ◽  
History Of

scholarly journals Family history of colorectal cancer and survival: a Swedish population‐based study

2020 ◽  
Vol 287 (6) ◽  
pp. 723-733 ◽  
Author(s):  
F. Pesola ◽  
S. Eloranta ◽  
A. Martling ◽  
D. Saraste ◽  
K. E. Smedby
Keyword(s):  
Colorectal Cancer ◽  
Family History ◽  
Population Based ◽  
Swedish Population ◽  
Population Based Study ◽  
History Of

scholarly journals Risk of colorectal cancer in patients with diabetes mellitus: A Swedish nationwide cohort study

PLoS Medicine ◽  
2020 ◽  
Vol 17 (11) ◽  
pp. e1003431
Author(s):  
Uzair Ali Khan ◽  
Mahdi Fallah ◽  
Kristina Sundquist ◽  
Jan Sundquist ◽  
Hermann Brenner ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Colorectal Cancer ◽  
Cohort Study ◽  
Family History ◽  
General Population ◽  
Early Onset ◽  
Swedish Population ◽  
Crc Screening ◽  
Patients With Diabetes ◽  
History Of

Background Colorectal cancer (CRC) incidence is increasing among young adults below screening age, despite the effectiveness of screening in older populations. Individuals with diabetes mellitus are at increased risk of early-onset CRC. We aimed to determine how many years earlier than the general population patients with diabetes with/without family history of CRC reach the threshold risk at which CRC screening is recommended to the general population. Methods and findings A nationwide cohort study (follow-up:1964–2015) involving all Swedish residents born after 1931 and their parents was carried out using record linkage of Swedish Population Register, Cancer Registry, National Patient Register, and Multi-Generation Register. Of 12,614,256 individuals who were followed between 1964 and 2015 (51% men; age range at baseline 0–107 years), 162,226 developed CRC, and 559,375 developed diabetes. Age-specific 10-year cumulative risk curves were used to draw conclusions about how many years earlier patients with diabetes reach the 10-year cumulative risks of CRC in 50-year-old men and women (most common age of first screening), which were 0.44% and 0.41%, respectively. Diabetic patients attained the screening level of CRC risk earlier than the general Swedish population. Men with diabetes reached 0.44% risk at age 45 (5 years earlier than the recommended age of screening). In women with diabetes, the risk advancement was 4 years. Risk was more pronounced for those with additional family history of CRC (12–21 years earlier depending on sex and benchmark starting age of screening). The study limitations include lack of detailed information on diabetes type, lifestyle factors, and colonoscopy data. Conclusions Using high-quality registers, this study is, to our knowledge, the first one that provides novel evidence-based information for risk-adapted starting ages of CRC screening for patients with diabetes, who are at higher risk of early-onset CRC than the general population.

Family History of Venous Thromboembolism As a Risk Factor for Thrombosis in Multiple Myeloma Patients: A Population-Based Study,

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 3987-3987
Author(s):  
Sigurdur Y Kristinsson ◽  
Lynn Goldin ◽  
Ingemar Turesson ◽  
Magnus Bjorkholm ◽  
Ola Landgren
Keyword(s):  
Multiple Myeloma ◽  
Risk Factor ◽  
Venous Thromboembolism ◽  
Family History ◽  
Large Population ◽  
Population Based ◽  
Population Based Study ◽  
Increased Risk ◽  
History Of ◽  
The Impact

Abstract Abstract 3987 Background: Patients with multiple myeloma are at an increased risk of venous thromboembolism (VTE), especially when treated with thalidomide and lenalidomide. The etiology of this is largely unknown, but probably involves both genetic and environmental factors. Family history of VTE is a known risk factor for VTE in the general population, including known inherited thrombophilic abnormalities. The influence of a family history of VTE as a potential risk factor for VTE in multiple myeloma patients is unknown. To expand our knowledge on this topic, we conducted a large population-based study based on all multiple myeloma patients diagnosed in Sweden 1958–2004. Patients and Methods: We assessed the impact of family history of VTE as a risk factor for VTE among 21,067 multiple myeloma patients and 83,094 matched controls. Data on multiple myeloma patients was gathered from the Swedish Cancer Registry, information on first-degree relatives from the national Multigenerational Registry, and occurrence of VTE from the nationwide Patient Registry. We calculated odds ratios (OR) and 95% confidence intervals (CI) using chi-square. Results: Of the 21,067 multiple myeloma patients included in the study (54% males, median age at diagnosis 71 years), 66% had an identifiable first-degree relative. VTE was diagnosed in 1,429 multiple myeloma patients, and 921 had a family history of VTE. Compared to multiple myeloma patients without a family history of VTE, multiple myeloma patients with a family history of VTE had a 2.2-fold (95% CI 1.8–2.7; p<0.001) higher risk of VTE. Among 4,986 controls that were diagnosed with VTE, 316 had a family history of VTE. Controls with a family history of VTE had a 1.5-fold (95% CI 1.3–1.7; p<0.001) increased risk of VTE compared to controls without a family history of VTE. The difference of the impact of family history of VTE on the risk of VTE in multiple myeloma patients versus controls was significant. Summary and Conclusions: In this large population-based study including more than 20,000 multiple myeloma patients, we found family history of VTE to have a larger impact on VTE risk in multiple myeloma than in matched controls. Our findings confirm that genetic factors contribute to thrombophilia in multiple myeloma and may have therapeutic implications regarding thromboprophylaxis and treatment. Disclosures: No relevant conflicts of interest to declare.

Reduced calf muscle pump function is a risk factor for venous thromboembolism: A population-based cohort study

Blood ◽  
2021 ◽  
Author(s):  
Damon E Houghton ◽  
Aneel A. Ashrani ◽  
David Liedl ◽  
Ramila A Mehta ◽  
David Hodge ◽  
...  
Keyword(s):  
Risk Factor ◽  
Cohort Study ◽  
Venous Thromboembolism ◽  
Population Based ◽  
Calf Muscle ◽  
Pump Function ◽  
Muscle Pump ◽  
Calf Muscle Pump ◽  
Rochester Epidemiology Project ◽  
History Of

The calf muscle pump is a major determinate of venous return in the legs but has not been studied as a risk factor for venous thromboembolism (VTE). A population-based cohort study of Olmsted County, Minnesota residents was performed using calf pump function (CPF) measurements from venous plethysmography studies from 1998-2015. Patients with a history of VTE were excluded. Nursing validated VTE outcomes from the Rochester Epidemiology Project were identified after the index study date and patients with reduced CPF (rCPF) were compared to patients with normal CPF. 1532 patients with recorded CPF (28% air and 72% strain gauge plethysmography) were included: 591 (38.5%) had normal CPF, 353 (23.0%) had unilateral rCPF, and 588 (38.3%) had bilateral rCPF. Any VTE occurred in 87 patients (5.7%) after a median follow-up of 11.7 years (range 0-22.0 years; Table 2). Comparing patients with bilateral reduced to bilateral normal CPF, the unadjusted HR for incident VTE was 2.0 (95% CI 1.2-3.4) and after adjusting for age, BMI, and CCI, the HR was 1.68 (95% CI 0.98-2.89). The adjusted HR for ipsilateral DVT was evaluated in 3,064 legs comparing legs with reduced to normal CPF and was 1.71 (95% CI 1.03-2.84). Mortality was significantly higher in both the bilateral (p&lt;0.001) and unilateral (p&lt;0.001) rCPF groups compared to normal CPF. Our results demonstrate that CPF is a risk factor for VTE in an otherwise low-risk ambulatory population and might be a useful component in risk stratification models.

Sign in / Sign up

Export Citation Format

Share Document